Immunovia Names 2026 Nomination Committee to Support U.S.-Focused Commercial Push

Immunovia AB ( (SE:IMMNOV) ) has shared an announcement.

Immunovia AB has appointed its 2026 Nomination Committee, in line with its governance rules, comprising representatives of its largest shareholders and the chairman of the board, together holding 2.88 percent of the company’s shares and votes as of 30 September 2025. The committee will prepare proposals for the 2026 Annual General Meeting on board composition, remuneration and auditor selection, with a stated focus on securing board members whose skills and experience support Immunovia’s transition into a commercial-stage company with a strategic emphasis on the U.S. market, underscoring the importance of governance alignment with its growth and commercialization ambitions.

The most recent analyst rating on (SE:IMMNOV) stock is a Hold with a SEK0.23 price target. To see the full list of analyst forecasts on Immunovia AB stock, see the SE:IMMNOV Stock Forecast page.

More about Immunovia AB

Immunovia AB is a Swedish diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes simple blood-based tests that detect proteins and antibodies indicating pancreatic cancer in high‑risk individuals, working with healthcare providers, experts and patient advocacy groups. With an estimated 1.8 million high‑risk individuals in the U.S., Immunovia is concentrating its commercial efforts on what it identifies as the world’s largest market for pancreatic cancer detection, and its shares are listed on Nasdaq Stockholm.

Average Trading Volume: 6,153,329

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK139.6M

See more data about IMMNOV stock on TipRanks’ Stock Analysis page.